Wells Fargo
ANAB icon

Wells Fargo’s AnaptysBio ANAB Stock Holding History

Wells Fargo’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50,000
Closed -$192K – 6159
2019
Q4 		$192K Buy
+50,000
New +$1.18M ﹤0.01% 4970

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wells Fargo's ANAB Position: Q1 2026 in Review

Wells Fargo increased its AnaptysBio (ANAB) stake by 49% in Q1 2026, buying an estimated $590K and bringing the position to 33,180 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3338.

Wells Fargo first reported a position in ANAB in Q1 2017 and has held it in 36 quarters since. The position peaked at $29.9M in Q3 2018. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Wells Fargo held 33,180 shares of AnaptysBio worth $1.84M as of Q1 2026.
  • Wells Fargo bought 10,973 AnaptysBio shares in Q1 2026, an estimated $590K.
  • AnaptysBio made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3338 holding.
  • Wells Fargo first reported a position in AnaptysBio in Q1 2017 and has held it in 36 quarters since.
  • Wells Fargo's AnaptysBio position peaked at $29.9M in Q3 2018.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.